Payment overview · 2025
General Payments
$57,508.93
66 reported records · 11 companies
Healthcare provider profile · identity verified
Rodney Anton Samaan, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MISSION HILLS, CA · NPI 1578776720
Verified facts
What the public records show
CMS Open Payments records show Rodney Anton Samaan, MD received $57,508.93 in general payments during 2025 across 66 reported records.
Novo Nordisk Inc accounted for 86.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Verquvo.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49,838.19 | 86.7% | 30 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $5,246.93 | 9.1% | 11 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $1,779.09 | 3.1% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $173.66 | 0.3% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $133.95 | 0.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $122.07 | 0.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $77.45 | 0.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$58.45 | 0.1% | 2 | 2025 |
| Lexicon Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.08 | 0.1% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $27.27 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.79 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $48,668.69 | 11 |
| Consulting Fee | $4,194.00 | 1 |
| Food and Beverage | $2,610.08 | 38 |
| Travel and Lodging | $2,036.16 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49,703.59 | 28 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $5,246.93 | 11 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,779.09 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $133.95 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $127.05 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $122.07 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $77.45 | 1 | 2025 |
Source payment records
|
|||||
| REVEAL LINQ Normalized: reveal linq |
Device | Medtronic, Inc. | $58.45 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.33 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.08 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 19 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Inpefa | Sotagliflozin | 273 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 56 |
| Atorvastatin Calcium | Atorvastatin Calcium | 168 | 55 |
| Ezetimibe | Ezetimibe | 104 | 32 |
| Ozempic | Semaglutide | 96 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 94 | 23 |
| Carvedilol | Carvedilol | 83 | 23 |
| Ranolazine Er | Ranolazine | 81 | 19 |
| Losartan Potassium | Losartan Potassium | 73 | 20 |
| Entresto | Sacubitril/Valsartan | 68 | 15 |
| Metformin Hcl | Metformin Hcl | 66 | 27 |
| Omeprazole | Omeprazole | 58 | 17 |
| Eliquis | Apixaban | 56 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 16 |
| Lisinopril | Lisinopril | 52 | 18 |
| Vascepa | Icosapent Ethyl | 52 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 19 |
| Allopurinol | Allopurinol | 36 | 12 |
| Furosemide | Furosemide | 35 | 11 |
| Acarbose | Acarbose | 33 | 13 |
| Jardiance | Empagliflozin | 32 | 15 |
| Levothyroxine Sodium | Levothyroxine Sodium | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Verquvo | Vericiguat | 31 | suppressed |
| Gabapentin | Gabapentin | 30 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 24 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 11 |
| Digoxin | Digoxin | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $57,508.93 · 66 records | Novo Nordisk Inc | CAPVAXIVE, ELIQUIS, FUROSCIX, JARDIANCE, Kerendia, Korlym, LifeVest, Ozempic, REVEAL LINQ, The Cologuard Plus Collection Kit, VERQUVO, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error